芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

sanoswiss uab - epirubicin hydrochloride - injektioneste, liuos - 2 mg/ml - epirubisiini

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

teva b.v. - sorafenibum tosylatum - tabletti, kalvopäällysteinen - 200 mg - sorafenibi

欧盟 - 芬兰文 - EMA (European Medicines Agency)

bayer ag - darolutamide - eturauhasen kasvaimet, kastraatio-resistentin - endokriinihoito - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

stada arzneimittel ag - sorafenib tosilate - tabletti, kalvopäällysteinen - 200 mg - sorafenibi

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

sandoz a/s - sorafenib tosilate - tabletti, kalvopäällysteinen - 200 mg - sorafenibi

欧盟 - 芬兰文 - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - rintojen kasvaimet - antineoplastiset aineet - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

mylan ab - sorafenib tosilate - tabletti, kalvopäällysteinen - 200 mg - sorafenibi

欧盟 - 芬兰文 - EMA (European Medicines Agency)

accord healthcare s.l.u. - abirateroniasetaatti - prostatiset kasvaimet - endokriinihoito - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

欧盟 - 芬兰文 - EMA (European Medicines Agency)

mylan ireland limited - abirateroniasetaatti - prostatiset kasvaimet - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

adalvo limited - enzalutamide - kapseli, pehmeä - 40 mg - entsalutamidi